Christine B. Hunter, R.N., CCRC

Instructor of Neurology

Graduate School

ADN (1990) Houston Community College

Clinical Interests

Movement disorders including Parkinson's disease, essential tremor, dystonia, Tourette's syndrome and Huntington's disease.

Research Interests

Experimental therapeutics and genetics of movement disorders.

Publications
Collapse All | Expand All

Frank S, Ondo W, Fahn S, Hunter C, Oakes D, Plumb S, Marshall F, Shoulson I, Eberly S, Walker F, Factor S, Hunt V, Shinaman A, Jankovic J. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol. 2008;31:127-33.
Kenney C, Hunter C, Davidson A, Jankovic J. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol. 2008;48:379-84.
Deng H, Le WD, Hunter CB, Mejia N, Xie WJ, Jankovic J. A family with Parkinson disease, essential tremor, bell palsy, and parkin mutations. Arch Neurol. 2007;64:421-4.
Ishihara L, Gibson RA, Warren L, Amouri R, Lyons K, Wielinski C, Hunter C, Swartz JE, Elango R, Akkari PA, Leppert D, Surh L, Reeves KH, Thomas S, Ragone L, Hattori N, Pahwa R, Jankovic J, Nance M, Freeman A, et al. Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov Disord. 2007;22:55-61.
Kenney C, Diamond A, Mejia N, Davidson A, Hunter C, Jankovic J. Distinguishing psychogenic and essential tremor. J Neurol Sci. 2007;263:94-9.
Kenney C, Hunter C, Davidson A, Jankovic J. Short-term effects of tetrabenazine on chorea associated with Huntington's disease. Mov Disord. 2007;22:10-3.
Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007;22:193-7.
Kenney C, Simpson R, Hunter C, Ondo W, Almaguer M, Davidson A, Jankovic J. Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders. J Neurosurg. 2007;106:621-5.
Ondo WG, Mejia NI, Hunter CB. A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. Parkinsonism Relat Disord. 2007;13:453-4.
Tan EK, Lee J, Hunter C, Shinawi L, Fook-Chong S, Jankovic J. Comparing knowledge and attitudes towards genetic testing in Parkinson's disease in an American and Asian population. J Neurol Sci. 2007;252:113-20.
Deng H, Le W, Guo Y, Hunter CB, Xie W, Huang M, Jankovic J. Genetic analysis of LRRK2 mutations in patients with Parkinson disease. J Neurol Sci. 2006;251:102-6.
Deng H, Le WD, Hunter CB, Ondo WG, Guo Y, Xie WJ, Jankovic J. Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations. Arch Neurol. 2006;63:273-7.
Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A, Comella CL, Gordon M, Riley DE, Sethi K, Singer C, Stacy M, Tarsy D, Atassi MZ. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006;67:2233-5.
Kenney C, Hunter C, Mejia N, Jankovic J. Is history of depression a contraindication to treatment with tetrabenazine? Clin Neuropharmacol. 2006;29:259-64.
Deng H, Le W, Guo Y, Hunter CB, Xie W, Jankovic J. Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation. Ann Neurol. 2005;57:933-4.
Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology. 2004;62:37-40.
Ondo WG, Hunter C. Flumazenil, a GABA antagonist, may improve features of Parkinson's disease. Mov Disord. 2003;18:683-5.
Jankovic J, Hunter C. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord. 2002;8:271-6.
Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord. 2002;17:1031-5.
Xu PY, Liang R, Jankovic J, Hunter C, Zeng YX, Ashizawa T, Lai D, Le WD. Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease. Neurology. 2002;58:881-4.
Ondo W, Hunter C, Vuong KD, Schwartz K, Jankovic J. Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. Mov Disord. 2000;15:678-82.
Ondo WG, Hunter C, Vuong KD, Jankovic J. The pharmacokinetic and clinical effects of tolcapone on a single dose of sublingual apomorphine in Parkinson's disease. Parkinsonism Relat Disord. 2000;6:237-240.
Ondo W, Hunter C, Almaguer M, Gancher S, Jankovic J. Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson's disease. Clin Neuropharmacol. 1999;22:1-4.
Ondo W, Hunter C, Almaguer M, Jankovic J. A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease. Mov Disord. 1999;14:664-8.

Poster Presentations
View Details | Collapse All | Expand All

Hunter CB, Aguilar LG, Nashatizadeh MM, Lay LF, Jankovic J. Evaluation of a Parkinson's disease screening questionnaire for use in a community-based setting. Mov Disord. 2008;23 Suppl 1:S361.
Jimenez-Shahed J, Hunter CB, Jankovic J. Acamprosate improves impulse control disorders in Parkinson's disease. Neurology. 2008;70(11 Suppl 1):A288.
Ondo WG, Hunter CB, Davidson A, Isaacson SH, Silver DE, Stewart RM, Tetrud JW. Tolerability and efficacy of switching from swallowed selegiline to zydis selegiline (Zelapar®) in patients with Parkinson's disease. Mov Disord. 2008;23 Suppl 1:S222.
Deng H, Le W, Guo Y, Hunter CB, Xie W, Huang M, Jankovic J. LRRK2 R1441C/G/H and G2019S mutations in patients with Parkinson's disease. Ann Neurol. 2006;60 Suppl 10:S74.
Deng H, Le W, Hunter CB, Xie W, Mejia N, Jankovic J. A Mexican pedigree with Parkinson's disease, essential tremor and bell's palsy associated with parkin but not HS1BP3 gene mutation. Ann Neurol. 2006;60 Suppl 10:S58.
Hunter CB, Kenney K, Mejia N, Davidson A, Jankovic J. Medications associated with the onset of tardive dyskinesia. Ann Neurol. 2006;60 Suppl 10:S76.
Hunter CB, Tan EK, Lee J, Shinawi LM, Fook-Chong S, Jankovic J. Comparing knowledge and attitudes towards genetic testing in Parkinson's disease in an American and Asian population. Mov Disord. 2006;21 Suppl 15:S411-2.
Kenney C, Diamond AL, Mejia N, Hunter CB, Jankovic J. Clinical features that distinguish psychogenic and essential tremor. Mov Disord. 2006;21 Suppl 15:S706.
Kenney C, Hunter CB, Davidson A, Jankovic J. Short-term effects of tetrabenazine on chorea associated with Huntington disease. Ann Neurol. 2006;60 Suppl 10:S78.
Kenney C, Hunter CB, Davidson A, Jankovic J. Short-term effects of tetrabenazine on chorea associated with Huntington disease. Mov Disord. 2006;21 Suppl 15:S635.
Kenney C, Simpson Jr RK, Hunter CB, Ondo WG, Almaguer M, Davidson A, Jankovic J. Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders. Neurology. 2006;66(5 Suppl 2):A49-50.
Kenney CJ, Vuong K, Hunter C, Almaguer M, Jankovic J. Long term safety of deep brain stimulation for the treatment of Parkinson's disease. Neurology. 2006;66(5 Suppl 2):A49-50.
Hunter C, Vuong KD, Mejia N, Jankovic J. Tetrabenazine: Does prior history of depression preclude this drug as a treatment option? Mov Disord. 2005:20 Suppl 10:S47.
Jankovic J, Hunter C, Atassi MZ, Dolimbek BZ, Dolimbek GS, and BOS Research Group. Botulinum toxin type B Observational Study (BOS). Mov Disord. 2005:20 Suppl 10:S31.
Jankovic J, Hunter CB, the BOS Study Group. Botulinum toxin type B Observational Study (BOS). Ann Neurol. 2005;58 Suppl 9:S54.
Mejia N, Vuong KD, Hunter C, Jankovic J. Medications associated with the onset of tardive dyskinesia. Mov Disord. 2005:20 Suppl 10:S18.
Mejia NI, Hunter C, Flores K, Ondo WG. A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. Mov Disord. 2005:20 Suppl 10:S10-1.
Hunter C, Vuong KD, Mejia N, Jankovic J. Tetrabenazine, a monoamine depleter, effective in the treatment of Tourette syndrome. Mov Disord. 2004:19 Suppl 9:S437.
Hunter CB, Vuong KD, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Neurology. 2004:62(7 Suppl S5):A506-7.
Jankovic J, Hunter C, Mejia N, Vuong KD. Tetrabenazine: Effective treatment for tardive dyskinesia. Mov Disord. 2004:19 Suppl 9:S73.
Jankovic J, Hunter CB, Vuong KD. Tetrabenazine in the treatment of chorea. American Society for Experimental NeuroTherapeutics (ASENT), 6th Annual Meeting in Bethesda, Maryland (March 11-13, 2004).
Jankovic J, Hunter CB, Vuong KD. Safety and efficacy of tetrabenazine in the treatment of Huntington's disease and other choreas. Mov Disord. 2004:19(9):1127.
Vuong KD, Hunter C, Mejia N, Jankovic J. Safety and efficacy of tetrabenazine in childhood hyperkinetic movement disorders. Mov Disord. 2004:19 Suppl 9:S422.
Ondo WG, Hunter CB, Moore W. A double blind placebo controlled parallel trial of botulinum toxin B (MyoblocT) for the treatment of sialorrhea in parkinson disease. Neurology. 2003;60(5 Suppl 1):A47-8.
Hunter CB, Wang A, Vuong KD, Jankovic J. Age-related tolerability of tetrabenazine. Mov Disord. 2002:17 Suppl 5:S41.
Hunter CB, Wang A, Vuong KD, Jankovic J. Tetrabenazine in the treatment of Tourette syndrome. Mov Disord. 2002:17 Suppl 5:S341.
Pan TH, Xu PY, Xie WJ, Hunter C, Jankovic J, Le WD. Upregulation of Nurr1 gene expression by dopamine receptor agonist pramipexole in human neuroblastoma SHSY-5Y cells. Mov Disord. 2002:17 Suppl 5:S84.
Ondo WG, Hunter C, Vuong KD, Jankovic J. Olanzapine treatment for dopaminergic induced hallucinations. Movement Disorder Society (MDS), 6th International Congress of Parkinson's Disease and Movement Disorders in Barcelona, Spain (June 11-15, 2000).

Contact Information

Christine B. Hunter, R.N., CCRC
Department of Neurology
Baylor College of Medicine
One Baylor Plaza, MS NB302
Houston, Texas 77030

Tel: 713-798-3951
Fax: 713-798-6808
Email: